Gennex Laboratories [GENNEX] vs Innova Captab [INNOVACAP] Detailed Stock Comparison
Gennex Laboratories
BSE
Loading...
Innova Captab
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Gennex Laboratories wins in 11 metrics, Innova Captab wins in 7 metrics, with 0 ties. Gennex Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Gennex Laboratories | Innova Captab | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 16.41 | 37.44 | Gennex Laboratories |
| Price-to-Book Ratio | 1.18 | 5.07 | Gennex Laboratories |
| Debt-to-Equity Ratio | 13.93 | 35.24 | Gennex Laboratories |
| PEG Ratio | 2.80 | 7.14 | Gennex Laboratories |
| EV/EBITDA | 15.81 | 26.94 | Gennex Laboratories |
| Profit Margin (TTM) | 11.46% | 9.98% | Gennex Laboratories |
| Operating Margin (TTM) | 13.37% | 11.68% | Gennex Laboratories |
| EBITDA Margin (TTM) | 13.37% | 11.68% | Gennex Laboratories |
| Return on Equity | 9.31% | 13.37% | Innova Captab |
| Return on Assets (TTM) | 7.08% | 8.12% | Innova Captab |
| Free Cash Flow (TTM) | $-197.44M | $-1.09B | Gennex Laboratories |
| 1-Year Return | -41.07% | 15.25% | Innova Captab |
| Price-to-Sales Ratio (TTM) | 2.16 | 3.74 | Gennex Laboratories |
| Enterprise Value | $2.75B | $51.37B | Innova Captab |
| EV/Revenue Ratio | 1.92 | 3.95 | Gennex Laboratories |
| Gross Profit Margin (TTM) | 35.05% | 37.21% | Innova Captab |
| Revenue per Share (TTM) | $7 | $227 | Innova Captab |
| Earnings per Share (Diluted) | $0.78 | $22.70 | Innova Captab |
| Beta (Stock Volatility) | 0.31 | N/A | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Gennex Laboratories vs Innova Captab Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -0.55% | 8.38% | 11.50% | 2.32% | -9.28% | -25.32% |
| Innova Captab | -2.09% | 0.59% | -7.07% | -0.71% | -5.56% | -23.39% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Gennex Laboratories | -41.07% | 96.92% | 228.21% | 181.32% | 759.06% | 975.63% |
| Innova Captab | 15.25% | 57.00% | 57.00% | 57.00% | 57.00% | 57.00% |
News Based Sentiment: Gennex Laboratories vs Innova Captab
Gennex Laboratories
News based Sentiment: MIXED
Gennex Laboratories experienced a stock price reversal and reported positive Q1 FY2026 results, but continues to face significant long-term declines and saw a large insider sell transaction. These mixed signals create a complex investment picture, making October a noteworthy but not transformative month for the company.
Innova Captab
News based Sentiment: POSITIVE
Innova Captab reported impressive revenue and profit growth for both Q1 FY2026 and the full fiscal year 2025-26, supported by a 'Buy' rating from JM Financial. While there were shifts in shareholding, particularly a decrease in FII holdings, the overall narrative points towards a positive trajectory for the company.
Performance & Financial Health Analysis: Gennex Laboratories vs Innova Captab
| Metric | GENNEX | INNOVACAP |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.11B | ₹48.64B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 642,874 | 33,824 |
| 90 Day Avg. Volume | 571,621 | 40,665 |
| Last Close | ₹12.73 | ₹832.25 |
| 52 Week Range | ₹10.84 - ₹19.00 | ₹662.00 - ₹1,260.00 |
| % from 52W High | -33.00% | -33.95% |
| All-Time High | ₹29.00 (Sep 16, 2024) | ₹1,260.00 (Jan 06, 2025) |
| % from All-Time High | -56.10% | -33.95% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.21% | 0.20% |
| Quarterly Earnings Growth | 0.08% | 0.05% |
| Financial Health | ||
| Profit Margin (TTM) | 0.11% | 0.10% |
| Operating Margin (TTM) | 0.13% | 0.12% |
| Return on Equity (TTM) | 0.09% | 0.13% |
| Debt to Equity (MRQ) | 13.93 | 35.24 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹10.85 | ₹167.66 |
| Cash per Share (MRQ) | ₹2.40 | ₹11.41 |
| Operating Cash Flow (TTM) | ₹-75,467,000 | ₹282.88M |
| Levered Free Cash Flow (TTM) | ₹181.23M | ₹1.28B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Gennex Laboratories vs Innova Captab
| Metric | GENNEX | INNOVACAP |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 16.41 | 37.44 |
| Forward P/E | N/A | 20.01 |
| PEG Ratio | 2.80 | 7.14 |
| Price to Sales (TTM) | 2.16 | 3.74 |
| Price to Book (MRQ) | 1.18 | 5.07 |
| Market Capitalization | ||
| Market Capitalization | ₹3.11B | ₹48.64B |
| Enterprise Value | ₹2.75B | ₹51.37B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.92 | 3.95 |
| Enterprise to EBITDA | 15.81 | 26.94 |
| Risk & Other Metrics | ||
| Beta | 0.31 | N/A |
| Book Value per Share (MRQ) | ₹10.85 | ₹167.66 |
Financial Statements Comparison: Gennex Laboratories vs Innova Captab
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | GENNEX | INNOVACAP |
|---|---|---|
| Revenue/Sales | ₹341.78M | ₹3.52B |
| Cost of Goods Sold | ₹221.97M | ₹2.21B |
| Gross Profit | ₹119.81M | ₹1.31B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹45.68M | ₹410.54M |
| EBITDA | ₹73.49M | ₹565.82M |
| Pre-Tax Income | ₹58.66M | ₹426.77M |
| Income Tax | ₹8.50M | ₹116.62M |
| Net Income (Profit) | ₹50.16M | ₹310.15M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | GENNEX | INNOVACAP |
|---|---|---|
| Cash & Equivalents | ₹545.89M | ₹155.19M |
| Total Current Assets | ₹1.81B | ₹7.03B |
| Total Current Liabilities | ₹445.55M | ₹3.53B |
| Long-Term Debt | ₹168.93M | ₹2.45B |
| Total Shareholders Equity | ₹1.95B | ₹9.59B |
| Retained Earnings | ₹562.59M | ₹4.53B |
| Property, Plant & Equipment | ₹88.69M | ₹442.93M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | GENNEX | INNOVACAP |
|---|---|---|
| Operating Cash Flow | N/A | ₹378.60M |
| Capital Expenditures | N/A | ₹-1.21B |
| Free Cash Flow | N/A | ₹-908.56M |
| Debt Repayment | N/A | ₹-7.69M |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | GENNEX | INNOVACAP |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 642,874 | 33,824 |
| Average Daily Volume (90 Day) | 571,621 | 40,665 |
| Shares Outstanding | 227.45M | 57.22M |
| Float Shares | 132.11M | 15.70M |
| % Held by Insiders | 0.31% | 0.72% |
| % Held by Institutions | 0.00% | 0.19% |
Dividend Analysis & Yield Comparison: Gennex Laboratories vs Innova Captab
| Metric | GENNEX | INNOVACAP |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |